Teachers Advisors LLC Acquires 9,890 Shares of Juno Therapeutics, Inc. (JUNO)
Teachers Advisors LLC boosted its holdings in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 15.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 74,255 shares of the biopharmaceutical company’s stock after buying an additional 9,890 shares during the quarter. Teachers Advisors LLC owned 0.07% of Juno Therapeutics worth $2,219,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of JUNO. Pacad Investment Ltd. purchased a new position in Juno Therapeutics during the 2nd quarter worth approximately $105,000. Great West Life Assurance Co. Can raised its position in Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the last quarter. Leisure Capital Management purchased a new position in Juno Therapeutics during the 2nd quarter worth approximately $255,000. Brighton Jones LLC purchased a new position in Juno Therapeutics during the 2nd quarter worth approximately $260,000. Finally, CAPROCK Group Inc. purchased a new position in Juno Therapeutics during the 2nd quarter worth approximately $299,000. 67.38% of the stock is owned by institutional investors.
Juno Therapeutics, Inc. (NASDAQ JUNO) opened at 43.71 on Friday. The stock’s market capitalization is $4.59 billion. Juno Therapeutics, Inc. has a 12-month low of $17.52 and a 12-month high of $47.03. The stock’s 50 day moving average is $43.47 and its 200 day moving average is $30.97.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter last year, the company earned ($0.64) EPS. Juno Therapeutics’s revenue for the quarter was down 22.8% compared to the same quarter last year. Equities research analysts forecast that Juno Therapeutics, Inc. will post ($3.08) EPS for the current fiscal year.
In other news, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the sale, the director now owns 788,985 shares in the company, valued at $23,937,804.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Insiders have sold 85,004 shares of company stock valued at $3,551,561 in the last 90 days. Company insiders own 15.26% of the company’s stock.
A number of equities analysts have issued reports on the stock. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Morgan Stanley raised their price target on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Monday, August 7th. Vetr lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 price target for the company. in a research report on Monday, August 7th. ValuEngine raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Finally, Barclays PLC assumed coverage on shares of Juno Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $37.83.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.